Brainstorm cell therapeutics and pluri partner to support nurown® phase 3b trial manufacturing

Memorandum of understanding has been signed new york , nov. 11, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a memorandum of understanding (mou) with pluri inc. (nasdaq: plur) through its wholly owned subsidiary ("pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture nurown® for use in brainstorm's planned phase 3b trial in amyotrophic lateral sclerosis (als). this mou enables brainstorm to begin transfer of its manufacturing technology and start producing nurown at pluri's manufacturing facility upon finalizing the binding definitive agreement.
BCLI Ratings Summary
BCLI Quant Ranking